Xtl Biopharmaceuticals (XTLB) Net Cash Flow (2009 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly Net Cash Flow of -$540000.0 for Q4 2024, down 6.51% on a QoQ basis from -$507000.0 in Q2 2016.

Xtl Biopharmaceuticals (XTLB) Net Cash Flow (2009 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Net Cash Flow for 9 consecutive years, with -$540000.0 the latest figure, recorded in Q4 2024.

Quarterly Net Cash Flow changed N/A year-over-year to -$540000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$540000.0 (changed N/A YoY) and the FY2025 annual result came in at -$295000.0, up 70.94% from the prior year.
Net Cash Flow declined to -$540000.0 in Q4 2024 per XTLB's latest filing, from -$507000.0 in the prior quarter.
Over the last five years, Net Cash Flow for XTLB reached as high as -$540000.0 in Q4 2024 and fell as low as -$540000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Oculis Holding AG	66,140.12 Bn	66,139.83 Bn	-	10.56 Mn
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-2.44 Mn
4	BeOne Medicines	471.41 Bn	466.62 Bn	1.35 Bn	224.46 Mn
5	Vertex Pharmaceuticals	122.15 Bn	114.90 Bn	2.59 Bn	457.40 Mn
6	Regeneron Pharmaceuticals	69.94 Bn	61.18 Bn	3.31 Bn	-152.20 Mn
7	Belite Bio	62.43 Bn	62.43 Bn	-	-
8	Argenx Se	55.85 Bn	50.67 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.48 Bn	34.47 Bn	959.66 Mn	60.68 Mn
10	Xtl Biopharmaceuticals	2.51 Bn	2.51 Bn	-	-

Download Data